TechMediaBreaks – NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K
NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, filed its Annual Report on Form 10-K for the fiscal year ended June 30, 2024, on September 27, 2024. The company reported cash and cash equivalents of $4.97 million, approximately $7.5 million in Net Property and Equipment (“P&E”) assets (after depreciation), and total current liabilities of approximately $1.36 million as of June 30, 2024. During fiscal 2024, the company utilized net cash of approximately $6.31 million for operating activities, including certain expenditures for Phase 1a/1b clinical trial of NV-387 and drug manufacturing costs for…